These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8809448)

  • 1. Erosive arthritis and posterior uveitis in Behçet's disease: treatment with interferon alpha and interferon gamma.
    Kötter I; Dürk H; Eckstein A; Zierhut M; Fierlbeck G; Saal JG
    Clin Exp Rheumatol; 1996; 14(3):313-5. PubMed ID: 8809448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The use of interferon alfa-2r in the treatment of autoimmune uveitis (primary or associated with Behçet's disease)].
    Sánchez Román J; Pulido Aguilera MC; Castillo Palma MJ; Ocaña Medina C; Toral Peña A; López-Checa F; Wichmann I
    Rev Clin Esp; 1996 May; 196(5):293-8. PubMed ID: 8768028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet's Uveitis: A Small Case Series.
    Celiker H; Kazokoglu H; Direskeneli H
    Ocul Immunol Inflamm; 2019; 27(1):15-22. PubMed ID: 28700247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease.
    Guillaume-Czitrom S; Berger C; Pajot C; Bodaghi B; Wechsler B; Kone-Paut I
    Rheumatology (Oxford); 2007 Oct; 46(10):1570-3. PubMed ID: 17702770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
    Park JY; Chung YR; Lee K; Song JH; Lee ES
    Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ocular manifestations in Behçet's disease].
    Zeghidi H; Saadoun D; Bodaghi B
    Rev Med Interne; 2014 Feb; 35(2):97-102. PubMed ID: 24290834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
    Zouboulis CC; Orfanos CE
    Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
    Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC
    Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.
    Aydinoglu-Candan Ö; Araz-Erşan B; Gul A; Badur S; Tugal-Tutkun I
    Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):457-65. PubMed ID: 25500983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Behçet's disease: uveitis-therapy with interferon alpha2a - prospective clinical study in 33 patients].
    Stübiger N; Kötter I; Deuter C; Zierhut M
    Klin Monbl Augenheilkd; 2001 Dec; 218(12):768-73. PubMed ID: 11805868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alpha for ocular Behçet's disease.
    Pivetti-Pezzi P; Accorinti M; Pirraglia MP; Priori R; Valesini G
    Acta Ophthalmol Scand; 1997 Dec; 75(6):720-2. PubMed ID: 9527339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
    Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease.
    Wechsler B; Bodaghi B; Huong DL; Fardeau C; Amoura Z; Cassoux N; Piette JC; LeHoang P
    Ocul Immunol Inflamm; 2000 Dec; 8(4):293-301. PubMed ID: 11262659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic interferon alpha 2b treatment in Behçet's syndrome.
    Hamuryudan V; Moral F; Yurdakul S; Mat C; Tüzün Y; Ozyazgan Y; Direskeneli H; Akoglu T; Yazici H
    J Rheumatol; 1994 Jun; 21(6):1098-100. PubMed ID: 7932420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic therapy for Behçet's uveitis: a systematic review.
    Uke P; Gorodkin R; Beare N
    Br J Ophthalmol; 2020 Aug; 104(8):1045-1051. PubMed ID: 31676596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease.
    Deuter CM; Zierhut M; Möhle A; Vonthein R; Stöbiger N; Kötter I
    Arthritis Rheum; 2010 Sep; 62(9):2796-805. PubMed ID: 20518075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of interferon alpha-2a therapy in patients with Behcet's disease.
    Yalçindağ FN; Uzun A
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature.
    Kötter I; Koch S; Vonthein R; Rückwaldt U; Amberger M; Günaydin I; Zierhut M; Stübiger N
    Clin Exp Rheumatol; 2005; 23(4 Suppl 38):S20-6. PubMed ID: 16273760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of interferon alpha 2A treatment in Behçet's disease.
    Boyvat A; Sişman-Solak C; Gürler A
    Dermatology; 2000; 201(1):40-3. PubMed ID: 10971058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.
    Kötter I; Eckstein AK; Stübiger N; Zierhut M
    Br J Ophthalmol; 1998 May; 82(5):488-94. PubMed ID: 9713053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.